Storia in 5 fonti

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo6 g fa

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

originale

Timeline cronologica

venerdì 4 settembre 2026·investors.com
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.
venerdì 4 settembre 2026·swissinfo.ch
Novartis Drug Fails Key Test for New Heart Disease Approach
(Bloomberg) -- A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a…

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Confronto fonti

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Timeline cronologica

Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Novartis Drug Fails Key Test for New Heart Disease Approach

Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Novartis Drug Fails Key Test for New Heart Disease Approach

‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events

Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly

Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly

‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events